TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Thromboprophylaxis During Bariatric Surgery
Brief Summary: This trial is an assessment of the efficacy of three thromboprophylaxis regimens in two types of bariatric surgery.

- gastric banding and gastric bypass on anti-Xa activity levels

The study includes two groups of 150 patients scheduled for gastric banding or gastric bypass.

Assessment of anti-Xa levels before and 4 hours after the injections from day 0 to 2 in order to determine the best prophylactic regimen allowing expected values ranged between 0.3 and 0.5 IU / ml.


Options:
A: Arm Label: 40mg Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: 40mg Enoxaparin | Arm Label: 60mg Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: 60mg Enoxaparin | Arm Label: Control; Type: OTHER; Interventions: Other: Control | Intervention Type: DRUG; Name: 40mg Enoxaparin; Assigned to Arm(s): 40mg Enoxaparin | Intervention Type: DRUG; Name: 60mg Enoxaparin; Assigned to Arm(s): 60mg Enoxaparin | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
B: Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): N/A
C: Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Drug: ASA, Drug: Clopidogrel 75mg | Arm Label: Apixaban group; Type: EXPERIMENTAL; Interventions: Drug: Apixaban, Drug: ASA | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban group | Intervention Type: DRUG; Name: ASA; Assigned to Arm(s): Apixaban group, Control group | Intervention Type: DRUG; Name: Clopidogrel 75mg; Assigned to Arm(s): Control group
D: Arm Label: Rivaroxaban 2.5mg + Aspirin 100mg; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939), Drug: Aspirin, Drug: Pantoprazole, Drug: Pantoprazole placebo | Arm Label: Rivaroxaban 5mg + Aspirin Placebo; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939), Drug: Aspirin placebo, Drug: Pantoprazole, Drug: Pantoprazole placebo | Arm Label: Rivaroxaban Placebo + Aspirin 100mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin, Drug: Rivaroxaban placebo, Drug: Pantoprazole, Drug: Pantoprazole placebo | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban 2.5mg + Aspirin 100mg | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban 5mg + Aspirin Placebo | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Rivaroxaban 2.5mg + Aspirin 100mg, Rivaroxaban Placebo + Aspirin 100mg | Intervention Type: DRUG; Name: Aspirin placebo; Assigned to Arm(s): Rivaroxaban 5mg + Aspirin Placebo | Intervention Type: DRUG; Name: Rivaroxaban placebo; Assigned to Arm(s): Rivaroxaban Placebo + Aspirin 100mg | Intervention Type: DRUG; Name: Pantoprazole; Assigned to Arm(s): Rivaroxaban 2.5mg + Aspirin 100mg, Rivaroxaban 5mg + Aspirin Placebo, Rivaroxaban Placebo + Aspirin 100mg | Intervention Type: DRUG; Name: Pantoprazole placebo; Assigned to Arm(s): Rivaroxaban 2.5mg + Aspirin 100mg, Rivaroxaban 5mg + Aspirin Placebo, Rivaroxaban Placebo + Aspirin 100mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Thromboprophylaxis During Bariatric Surgery
Brief Summary: This trial is an assessment of the efficacy of three thromboprophylaxis regimens in two types of bariatric surgery.

- gastric banding and gastric bypass on anti-Xa activity levels

The study includes two groups of 150 patients scheduled for gastric banding or gastric bypass.

Assessment of anti-Xa levels before and 4 hours after the injections from day 0 to 2 in order to determine the best prophylactic regimen allowing expected values ranged between 0.3 and 0.5 IU / ml.


Options:
A: Arm Label: Active Coagulation; Type: EXPERIMENTAL; Interventions: Drug: Tinzaparin or unfractionated heparin | Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Tinzaparin or unfractionated heparin; Assigned to Arm(s): Active Coagulation
B: Arm Label: Cohort 1 dociparstat; Type: EXPERIMENTAL; Interventions: Drug: Dociparstat sodium | Arm Label: Cohort 1 placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cohort 2 dociparstat; Type: EXPERIMENTAL; Interventions: Drug: Dociparstat sodium | Arm Label: Cohort 2 placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cohort 3 dociparstat; Type: EXPERIMENTAL; Interventions: Drug: Dociparstat sodium | Arm Label: Cohort 3 placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dociparstat sodium; Assigned to Arm(s): Cohort 1 dociparstat, Cohort 2 dociparstat, Cohort 3 dociparstat | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 placebo, Cohort 2 placebo, Cohort 3 placebo
C: Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): N/A
D: Arm Label: Low Prophylactic Dose of Low Molecular Weight Heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Arm Label: Weight-Adjusted Prophylactic Dose Low Molecular Weight Heparin; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Weight-Adjusted Prophylactic Dose Low Molecular Weight Heparin | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Low Prophylactic Dose of Low Molecular Weight Heparin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Thromboprophylaxis During Bariatric Surgery
Brief Summary: This trial is an assessment of the efficacy of three thromboprophylaxis regimens in two types of bariatric surgery.

- gastric banding and gastric bypass on anti-Xa activity levels

The study includes two groups of 150 patients scheduled for gastric banding or gastric bypass.

Assessment of anti-Xa levels before and 4 hours after the injections from day 0 to 2 in order to determine the best prophylactic regimen allowing expected values ranged between 0.3 and 0.5 IU / ml.


Options:
A: Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): N/A
B: Arm Label: 40 mg subcutaneous enoxaparin o.d.; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Arm Label: 40 mg subcutaneous enoxaparin b.i.d; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): 40 mg subcutaneous enoxaparin b.i.d, 40 mg subcutaneous enoxaparin o.d.
C: Intervention Type: DRUG; Name: chlorthalidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atenolol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: reserpine; Assigned to Arm(s): N/A
D: Arm Label: Therapeutic anticoagulation; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparin | Arm Label: Prophylactic anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Prophylactic anticoagulation, Therapeutic anticoagulation

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter Study for Anti-oxidative and Anti-inflammatory Effects of Pitavastatin in Hypercholesterolemic Patients With Metabolic Syndrome
Brief Summary: The purpose of this study is to evaluate anti-oxidative and anti-inflammatory effects of pitavastatin in hypercholesterolemic patients with the metabolic syndrome.


Options:
A: Intervention Type: DRUG; Name: pitavastatin; Assigned to Arm(s): N/A
B: Arm Label: pitavastatin 4 mg once daily (QD); Type: EXPERIMENTAL; Interventions: Drug: pitavastatin | Arm Label: pravastatin 40 mg once daily (QD); Type: ACTIVE_COMPARATOR; Interventions: Drug: pravastatin | Intervention Type: DRUG; Name: pitavastatin; Assigned to Arm(s): pitavastatin 4 mg once daily (QD) | Intervention Type: DRUG; Name: pravastatin; Assigned to Arm(s): pravastatin 40 mg once daily (QD)
C: Arm Label: Pitavastatin 4 mg QD; Type: EXPERIMENTAL; Interventions: Drug: pitavastatin | Arm Label: Simvastatin 40 mg QD; Type: ACTIVE_COMPARATOR; Interventions: Drug: simvastatin | Intervention Type: DRUG; Name: pitavastatin; Assigned to Arm(s): Pitavastatin 4 mg QD | Intervention Type: DRUG; Name: simvastatin; Assigned to Arm(s): Simvastatin 40 mg QD
D: Arm Label: Pitavastatin; Type: EXPERIMENTAL; Interventions: Drug: Pitavastatin | Arm Label: Atorvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Intervention Type: DRUG; Name: Pitavastatin; Assigned to Arm(s): Pitavastatin | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Positive Impact of Endovascular Options for Treating Aneurysms Early (PIVOTAL)
Brief Summary: The purpose of this study is to compare endovascular repair using any FDA approved Medtronic AAA Stent Graft System versus surveillance in subjects with smaller abdominal aortic aneurysms (AAA)(4-5CM), with respect to AAA rupture and AAA related deaths.


Options:
A: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard Open Repair | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Endovascular Repair | Intervention Type: PROCEDURE; Name: Endovascular Repair; Assigned to Arm(s): Arm 2 | Intervention Type: PROCEDURE; Name: Standard Open Repair; Assigned to Arm(s): Arm 1
B: Arm Label: Surveillance; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Early Endovascular Repair; Type: EXPERIMENTAL; Interventions: Device: AneuRx AAA stent graft / Talent AAA stent graft | Intervention Type: DEVICE; Name: AneuRx AAA stent graft / Talent AAA stent graft; Assigned to Arm(s): Early Endovascular Repair
C: Arm Label: EVAR; Type: EXPERIMENTAL; Interventions: Procedure: EVAR (Endovascular repair of Abdominal Aortic aneurysm) | Arm Label: Surveillance; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surveillance | Intervention Type: PROCEDURE; Name: EVAR (Endovascular repair of Abdominal Aortic aneurysm); Assigned to Arm(s): EVAR | Intervention Type: PROCEDURE; Name: Surveillance; Assigned to Arm(s): Surveillance
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Open repair | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Endovascular repair (with endograft) | Intervention Type: PROCEDURE; Name: Endovascular repair (with endograft); Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Open repair; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Positive Impact of Endovascular Options for Treating Aneurysms Early (PIVOTAL)
Brief Summary: The purpose of this study is to compare endovascular repair using any FDA approved Medtronic AAA Stent Graft System versus surveillance in subjects with smaller abdominal aortic aneurysms (AAA)(4-5CM), with respect to AAA rupture and AAA related deaths.


Options:
A: Arm Label: Surveillance; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Early Endovascular Repair; Type: EXPERIMENTAL; Interventions: Device: AneuRx AAA stent graft / Talent AAA stent graft | Intervention Type: DEVICE; Name: AneuRx AAA stent graft / Talent AAA stent graft; Assigned to Arm(s): Early Endovascular Repair
B: Arm Label: OR; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Open Aneurysm Repair | Arm Label: EVAR; Type: EXPERIMENTAL; Interventions: Procedure: Endovascular Aneurysm Repair | Intervention Type: PROCEDURE; Name: Open Aneurysm Repair; Assigned to Arm(s): OR | Intervention Type: PROCEDURE; Name: Endovascular Aneurysm Repair; Assigned to Arm(s): EVAR
C: Arm Label: EVAR; Type: EXPERIMENTAL; Interventions: Procedure: EVAR (Endovascular repair of Abdominal Aortic aneurysm) | Arm Label: Surveillance; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surveillance | Intervention Type: PROCEDURE; Name: EVAR (Endovascular repair of Abdominal Aortic aneurysm); Assigned to Arm(s): EVAR | Intervention Type: PROCEDURE; Name: Surveillance; Assigned to Arm(s): Surveillance
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Open repair | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Endovascular repair (with endograft) | Intervention Type: PROCEDURE; Name: Endovascular repair (with endograft); Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Open repair; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prednisolone vs. Ciclosporine in Severe Atopic Eczema
Brief Summary: To investigate the comparative efficacy of Ciclosporine A and Prednisolone in adult patients with severe atopic dermatitis.


Options:
A: Arm Label: Placebo qw; Type: EXPERIMENTAL; Interventions: Drug: Placebo (for Dupilumab), Other: Topical Corticosteroid (TCS) | Arm Label: Dupilumab 300 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo (for Dupilumab), Other: Topical Corticosteroid (TCS) | Arm Label: Dupilumab 300 mg qw; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Other: Topical Corticosteroid (TCS) | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 300 mg q2w, Dupilumab 300 mg qw | Intervention Type: DRUG; Name: Placebo (for Dupilumab); Assigned to Arm(s): Dupilumab 300 mg q2w, Placebo qw | Intervention Type: OTHER; Name: Topical Corticosteroid (TCS); Assigned to Arm(s): Dupilumab 300 mg q2w, Dupilumab 300 mg qw, Placebo qw
B: Arm Label: Placebo qw; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Other: Background treatment | Arm Label: Dupilumab 200 mg qw; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Other: Background treatment | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 200 mg qw | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo qw | Intervention Type: OTHER; Name: Background treatment; Assigned to Arm(s): Dupilumab 200 mg qw, Placebo qw
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prednisolone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclosporine A | Intervention Type: DRUG; Name: Prednisolone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Ciclosporine A; Assigned to Arm(s): 2
D: Arm Label: MEDI9929 280 mg; Type: EXPERIMENTAL; Interventions: Biological: MEDI9929 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: MEDI9929; Assigned to Arm(s): MEDI9929 280 mg | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Automatic Control of Pressure Support Ventilation in Surgical Intensive Care Units - a Bicentric, Prospective, Randomized, Controlled Trial
Brief Summary: This bicentric, randomized, controlled trial examines the effectiveness of an automatic control of pressure support ventilation (SmartCare/PS) in critically ill patients.


Options:
A: Intervention Type: DEVICE; Name: SmartCare/PS; Assigned to Arm(s): N/A
B: Arm Label: Automated settings; Type: EXPERIMENTAL; Interventions: Device: Hamilton ventilator (G5 modify to S1) Automated settings | Arm Label: protocolized settings; Type: ACTIVE_COMPARATOR; Interventions: Other: Hamilton ventilator (G5) protocolized settings | Intervention Type: DEVICE; Name: Hamilton ventilator (G5 modify to S1) Automated settings; Assigned to Arm(s): Automated settings | Intervention Type: OTHER; Name: Hamilton ventilator (G5) protocolized settings; Assigned to Arm(s): protocolized settings
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Smartcare/PS | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Smartcare/PS; Assigned to Arm(s): 1
D: Arm Label: Adaptive support ventilation in ARDS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: type of mechanical ventilation | Arm Label: conventional ventilation strategy in ARDS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: type of mechanical ventilation | Intervention Type: PROCEDURE; Name: type of mechanical ventilation; Assigned to Arm(s): Adaptive support ventilation in ARDS, conventional ventilation strategy in ARDS

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Clinical Trial Comparing the Effect of 1g of Daily Cinnamon Plus Usual Care to Usual Cre on the Hemoglobin A1c of Uncontrolled Type 2 Diabetics
Brief Summary: This study will randomize diabetics with hemoglobin A1c greater than 7.0 to receive either cinnamon plus usual care or usual care alone. Hemoglobin A1c will be measured at intake and after 90 days.


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cinnamon or placebo 500 mg capsule twice daily | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cinnamon or placebo 500 mg capsule twice daily | Intervention Type: DRUG; Name: Cinnamon or placebo 500 mg capsule twice daily; Assigned to Arm(s): 1, 2
B: Intervention Type: DRUG; Name: human insulin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin aspart; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: cinnamon; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Coccinia Cordifolia (herbal extract); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Randomized, Double-blind, Placebo-controlled Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease
Brief Summary: To demonstrate the efficacy and safety of adalimumab for the maintenance of clinical remission in Japanese subjects with Crohn's disease.


Options:
A: Arm Label: Usual Care practice; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment Algorithm; Type: ACTIVE_COMPARATOR; Interventions: Other: Treatment Algorithm for Crohn's Disease | Intervention Type: OTHER; Name: Treatment Algorithm for Crohn's Disease; Assigned to Arm(s): Treatment Algorithm
B: Arm Label: DB Adalimumab 40 mg eow; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Placebo eow; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: OL Adalimumab 40 mg eow; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): DB Adalimumab 40 mg eow, OL Adalimumab 40 mg eow | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo eow
C: Arm Label: Active arm; Type: ACTIVE_COMPARATOR; Interventions: Procedure: endoscopy | Arm Label: Standard care arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: endoscopy; Assigned to Arm(s): Active arm
D: Arm Label: Adalimumab 160 mg/80 mg; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Adalimumab 80 mg/40 mg; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab 160 mg/80 mg | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab 80 mg/40 mg | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Randomized, Double-blind, Placebo-controlled Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease
Brief Summary: To demonstrate the efficacy and safety of adalimumab for the maintenance of clinical remission in Japanese subjects with Crohn's disease.


Options:
A: Arm Label: DB Adalimumab 40 mg eow; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Placebo eow; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: OL Adalimumab 40 mg eow; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): DB Adalimumab 40 mg eow, OL Adalimumab 40 mg eow | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo eow
B: Arm Label: Adalimumab 160 mg/80 mg; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Adalimumab 80 mg/40 mg; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab 160 mg/80 mg | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab 80 mg/40 mg | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: Open-label adalimumab (Week 0 to Week 4); Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Arm Label: Low-Dose Adalimumab: 20 mg or 10 mg eow (Week 4 to Week 52); Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Arm Label: High-Dose Adalimumab: 40 mg or 20 mg eow (Week 4 to Week 52); Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Open-label adalimumab (Week 0 to Week 4) | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Low-Dose Adalimumab: 20 mg or 10 mg eow (Week 4 to Week 52) | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): High-Dose Adalimumab: 40 mg or 20 mg eow (Week 4 to Week 52)
D: Arm Label: Any adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Any adalimumab

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Randomized, Double-blind, Placebo-controlled Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease
Brief Summary: The purpose of this study is to demonstrate the efficacy and safety of adalimumab for the induction of clinical remission in Japanese subjects with Crohn's disease.


Options:
A: Arm Label: Active arm; Type: ACTIVE_COMPARATOR; Interventions: Procedure: endoscopy | Arm Label: Standard care arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: endoscopy; Assigned to Arm(s): Active arm
B: Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): N/A
C: Arm Label: Adalimumab 160 mg/80 mg; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Adalimumab 80 mg/40 mg; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab 160 mg/80 mg | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab 80 mg/40 mg | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: DB Adalimumab 40 mg eow; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Placebo eow; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: OL Adalimumab 40 mg eow; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): DB Adalimumab 40 mg eow, OL Adalimumab 40 mg eow | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo eow

Answer: C